 CAMBRIDGE, Mass., April 28, 2021 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27. 